An oncogene is a gene that, when altered or abnormally expressed, can push a cell toward uncontrolled growth and contribute to the development of cancer. In healthy tissue many genes support normal growth, division and survival; oncogenes are typically mutated or misregulated versions of these normal genes, called proto-oncogenes. Activation of an oncogene can disturb cell-cycle control, promote proliferation, or help cells evade programmed death ( apoptosis ).

Definition and biological role

Proto-oncogenes encode proteins that participate in signaling pathways, transcriptional control, or the regulation of cell growth. When a proto-oncogene becomes an oncogene it gains one or more of the following properties: increased expression, a change in activity that makes the protein constitutively active, or altered regulation that disconnects it from normal cellular controls. Such changes can be caused by point mutations, gene amplification, chromosomal translocations, or insertion of viral sequences. The result is often sustained proliferative signaling and resistance to normal growth-limiting mechanisms.

Mechanisms of activation

  • Point mutations that alter protein function or activity.
  • Gene amplification leading to overproduction of an oncogenic protein.
  • Chromosomal translocations that create fusion proteins or place a gene under a new promoter.
  • Insertional mutagenesis by viruses or other mobile elements.

These changes convert a regulated proto-oncogene into an oncogene capable of driving abnormal division. However, oncogene activation is usually not sufficient by itself to produce a malignant tumor; additional genetic or environmental events typically cooperate to complete the transformation process.

Examples and clinical relevance

Several oncogenes are well characterized and important in human disease. Examples include members of the RAS family, the MYC transcription factors, BCR-ABL fusion from a translocation in certain leukemias, and ERBB2/HER2 amplification in some breast cancers. Detection of oncogene alterations can guide diagnosis, prognosis, and treatment selection. Many modern therapies act by targeting the protein products of oncogenes, for example kinase inhibitors or monoclonal antibodies directed against overactive receptors.

Historical perspective

The connection between viral cancer agents and cellular genes led to identification of cellular proto-oncogenes in the 1970s. In a pivotal series of experiments, researchers demonstrated that oncogenes are activated forms of normal cellular genes, a discovery recognized by the 1989 Nobel Prize awarded to J. Michael Bishop and Harold E. Varmus; their work explained how genes present in normal genomes can become drivers of malignant transformation and highlighted evolutionary conservation of key growth regulators. Since that time, dozens of oncogenes have been described across many organisms.

Distinctions, diagnostics and ongoing research

Oncogenes differ conceptually from tumor suppressor genes: oncogenes promote growth when activated, whereas tumor suppressors normally limit growth and lead to cancer when lost or inactivated. Modern cancer genomics screens for both types of alterations. Research continues to map signaling networks downstream of oncogenes, to find resistance mechanisms to targeted therapies, and to develop new agents that inhibit oncogene-driven pathways. Understanding how oncogenes interact with cellular systems and environmental factors remains central to cancer biology and therapy development. For more technical summaries and reviews see specialized resources and clinical guidelines (overview, mutation mechanisms, expression studies, apoptosis links, historical sources).